Dover has entered into a definitive agreement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will increase Dover’s biopharma single-use manufacturing offering, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income in the course of the full 12 months 2022.
When the deal closes, Malema will turn into part of the PSG enterprise unit within Dover’s Pumps & Process Solutions segment.
“We see an amazing long-term development opportunity within the bioprocessing industry pushed by a strong and growing pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, เกจวัดแรงดันน้ำไทวัสดุ growing adoption of more environment friendly single-use manufacturing processes supports a sturdy outlook for our choices of single-use parts to end-customers. We believe that pairing Malema’s expertise with our existing portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and value proposition of our options to our clients.”
“We are methodically building out our biopharma platform by way of proactive capacity additions, new product growth, and opportunistic acquisitions of highly-attractive niche component applied sciences,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and further strengthens our sensor portfolio with new proprietary know-how. In addition to attractive biopharma purposes, we expect sturdy growth in the semiconductor area on the capacity growth and re-shoring tailwinds.”
Share